Literature DB >> 35181823

Romosozumab and cardiovascular safety-should we learn lessons from pioglitazone?

Jubbin Jagan Jacob1, Thomas V Paul2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35181823     DOI： 10.1007/s00198-021-06271-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   5.071


× No keyword cloud information.
  12 in total

Review 1.  The WNT system: background and its role in bone.

Authors:  U H Lerner; C Ohlsson
Journal:  J Intern Med       Date:  2015-06       Impact factor: 8.989

2.  Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population.

Authors:  Wolfram Doehner; Erland Erdmann; Richard Cairns; Andrew L Clark; John A Dormandy; Ele Ferrannini; Stefan D Anker
Journal:  Int J Cardiol       Date:  2011-10-29       Impact factor: 4.164

3.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

4.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

Authors:  Felicia Cosman; Daria B Crittenden; Jonathan D Adachi; Neil Binkley; Edward Czerwinski; Serge Ferrari; Lorenz C Hofbauer; Edith Lau; E Michael Lewiecki; Akimitsu Miyauchi; Cristiano A F Zerbini; Cassandra E Milmont; Li Chen; Judy Maddox; Paul D Meisner; Cesar Libanati; Andreas Grauer
Journal:  N Engl J Med       Date:  2016-09-18       Impact factor: 91.245

Review 5.  Sclerostin: Intracellular mechanisms of action and its role in the pathogenesis of skeletal and vascular disorders.

Authors:  Barbara Pietrzyk; Mike Smertka; Jerzy Chudek
Journal:  Adv Clin Exp Med       Date:  2017-11       Impact factor: 1.727

Review 6.  Regulation of bone mass by Wnt signaling.

Authors:  Venkatesh Krishnan; Henry U Bryant; Ormond A Macdougald
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

7.  Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study.

Authors:  A Tominaga; K Wada; K Okazaki; H Nishi; Y Terayama; Y Kato
Journal:  Osteoporos Int       Date:  2021-03-26       Impact factor: 4.507

8.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.

Authors:  Kenneth G Saag; Jeffrey Petersen; Maria Luisa Brandi; Andrew C Karaplis; Mattias Lorentzon; Thierry Thomas; Judy Maddox; Michelle Fan; Paul D Meisner; Andreas Grauer
Journal:  N Engl J Med       Date:  2017-09-11       Impact factor: 91.245

9.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Authors:  Walter N Kernan; Catherine M Viscoli; Karen L Furie; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Peter D Guarino; Anne M Lovejoy; Peter N Peduzzi; Robin Conwit; Lawrence M Brass; Gregory G Schwartz; Harold P Adams; Leo Berger; Antonio Carolei; Wayne Clark; Bruce Coull; Gary A Ford; Dawn Kleindorfer; John R O'Leary; Mark W Parsons; Peter Ringleb; Souvik Sen; J David Spence; David Tanne; David Wang; Toni R Winder
Journal:  N Engl J Med       Date:  2016-02-17       Impact factor: 91.245

Review 10.  Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials.

Authors:  Marit de Jong; H Bart van der Worp; Yolanda van der Graaf; Frank L J Visseren; Jan Westerink
Journal:  Cardiovasc Diabetol       Date:  2017-10-16       Impact factor: 9.951
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.